OpenURL Connection Search

Select item for more details and to access through your institution.

Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry.
Published in:
2020
By:
- Mato, Anthony R.;
- Barrientos, Jacqueline C.;
- Ghosh, Nilanjan;
- Pagel, John M.;
- Brander, Danielle M.;
- Gutierrez, Meghan;
- Kadish, Karen;
- Tomlinson, Brian;
- Iyengar, Reethi;
- Ipe, David;
- Upasani, Sandhya;
- Amaya-Chanaga, Carlos I.;
- Sundaram, Murali;
- Han, Jennifer;
- Giafis, Nick;
- Sharman, Jeff P.
Publication type:
journal article
Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.
Published in:
Journal of Hematology & Oncology, 2017, v. 10, p. 1, doi. 10.1186/s13045-017-0435-x
By:
- Kashyap, Manoj K.;
- Amaya-Chanaga, Carlos I.;
- Kumar, Deepak;
- Simmons, Brett;
- Huser, Nanni;
- Yin Gu;
- Hallin, Max;
- Lindquist, Kevin;
- Yafawi, Rolla;
- Choi, Michael Y.;
- Amine, Ale-Ali;
- Rassenti, Laura Z.;
- Zhang, Cathy;
- Shu-Hui Liu;
- Smeal, Tod;
- Fantin, Valeria R.;
- Kipps, Thomas J.;
- Pernasetti, Flavia;
- Castro, Januario E.
Publication type:
Article
Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576
Published in:
Advances in Hematology, 2022, p. 1, doi. 10.1155/2022/4450824
By:
- Castro, Januario E.;
- Lengerke-Diaz, Paula A.;
- Velez Lujan, Juliana;
- Choi, Michael Y.;
- Moreno-Cortes, Eider F.;
- Forero, Jose V.;
- Garcia-Robledo, Juan Esteban;
- Jacobs, Chaja;
- McCarthy, Colin;
- Heinen, Alaina;
- Amaya-Chanaga, Carlos I.;
- Kipps, Thomas J.
Publication type:
Article

Found: 3

Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry.

Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.

Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576